Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Hemodialysis Patients With Heart Failure
NCT05141552Unknown
- Sponsor
- Renji Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in heart failure (HF) (2 arms), sponsored by Renji Hospital. Primary endpoint: Number of patients with hypoglycemia or urinary tract infection at 12 weeks. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05141552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141552.